TFM-4AS-1 is a dual selective androgen receptor modulator (SARM) and 5ñ-reductase inhibitor. It is a potent and selective partial agonist (E<sub>max</sub> = 55%) of the androgen receptor (IC<sub>50</sub> = 30nM) and inhibitor of 5ñ-reductase types I and II (IC<sub>50</sub> = 2 and 3 nM, respectively). TFM-4AS-1 shows tissue-selective androgenic effects; it promotes the accumulation of bone and muscle mass and has reduced effects in reproductive tissues and sebaceous glands. In an animal study, TFM-4AS-1 stimulated sebaceous gland formation only 31% as much as dihydrotestosterone (DHT) at doses that were as anabolic or more so than DHT. In addition, TFM-4AS-1 only weakly promoted growth of the prostate gland and it partially antagonized the actions of DHT in the seminal vesicles and endogenous androgens in the prostate gland. Structurally, TFM-4AS-1 is a 4-azasteroid. A structurally related and more advanced version of TFM-4AS-1, MK-0773, was developed and pursued for potential pharmaceutical use.